Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Indian share markets open in the red
Mon, 14 Jul 09:30 am

Barring Singapore (down 0.1%) and Indonesia (down 0.2%), the major Asian stock markets have opened on a positive note with stock markets in Japan (up 0.4%) and Hong Kong (up 0.4%) leading the gains.

The Indian share markets have opened the day in the red. The sectoral indices have opened mixed with consumer durables and software sector leading the losses. However, stocks in the capital goods and energy sector have opened on a firm note.

The Sensex today is down by around 52 points (0.2%), while the NSE-Nifty is down by around 16 points (0.2%). The midcap and smallcap stocks have also opened in the red with BSE Mid Cap and BSE Small Cap indices down by around 0.5% and 0.7% respectively. The rupee is currently trading at Rs 59.99 to the US dollar.

Pharma stocks have opened the day mainly in the red with Sun Pharmaceuticals Industries Ltd and Natco Pharma Ltd leading the losses. As per a leading financial daily, Sun Pharmaceutical Industries' subsidiary Caraco Pharmaceutical Laboratories has started recalling some batches of Venlafaxine Hydrochloride extended-release tablets from the US market. Venlafaxine Hydrochloride extended-release tablets are indicated for the treatment of major depressive disorder. According per the USFDA notification, the recall of 26,530 units of 30-count bottles and 14,597 units of 90-count bottles is voluntarily initiated by the company through a letter to the regulator last month under 'Class-II' classification. As per the FDA, stability results have found the product did not meet the drug release dissolution specifications.

Auto stocks have opened the day on a mixed note with TVS Motors Ltd and Escorts Ltd leading the gains. However, Tube Investments Ltd and Ashok Leyland Ltd were facing selling pressure. Tata Motors has registered 10.46% year on year (YoY) decline in global sales, including that of Jaguar Land Rover (JLR) for the month of June 2014. The auto sales volumes in June 2014 stood at 75,623 units, as compared to 84,458 units sold in the corresponding month last year. In the passenger vehicles category, the global sales of Tata Motors were at 44,239 units, versus 42,881 units in June 2013, up 3.16%. Meanwhile, sales of luxury brand Jaguar Land Rover increased 17.96% YoY, to 36,021 units in June, compared to 30,536 units in the same month last year. However, sales of commercial vehicles declined 24.51% YoY in June 2014 to 31,384 units from 41,577 units a year ago.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian share markets open in the red". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.